‘What We’re Really Focused On Is Internationalization’ – Aspire CEO Sets Out Strategy

Richard Condon Discusses Canute Deal And Future Growth Plans

In the wake of its recent acquisition of dermatology assets from Canute Pharma, UK-based Aspire Pharma is looking to new frontiers of expansion in Europe and beyond. Chief executive Richard Condon talks to Generics Bulletin about the next steps on the niche generics and value added medicines firm’s journey.

Richard Condon talks to Generics Bulletin about Aspire’s strategy (Aspire)

More from Interviews

More from Business